Newly published review highlights the crucial role of Daxor’s blood volume analysis technology in improving the management of cardiorenal syndrome Page 1

Review published in the prestigious journal Cardiorenal Medicine

Oak Ridge, TN, September 12, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced a review published in the journal Cardiorenal medicine that delves deeper into the complex landscape of cardiorenal syndrome (CRS) and highlights the critical role of blood volume analysis (BVA) in improving patient care and outcomes.

Key findings: